vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners began coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 price objective on the stock.

vTv Therapeutics Trading Down 3.3 %

VTVT stock opened at $20.20 on Friday. vTv Therapeutics has a twelve month low of $8.10 and a twelve month high of $30.99. The company’s 50 day moving average is $15.68 and its two-hundred day moving average is $15.09. The stock has a market cap of $64.44 million, a P/E ratio of -4.46 and a beta of 0.73.

Hedge Funds Weigh In On vTv Therapeutics

A number of institutional investors have recently modified their holdings of VTVT. JPMorgan Chase & Co. acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $25,000. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares during the period. Finally, FMR LLC acquired a new position in shares of vTv Therapeutics in the 3rd quarter valued at $2,402,000. 17.51% of the stock is owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.